Alivus Life Sciences Ltd share price logo

Alivus Life Sciences Ltd Share Price

(ALIVUS)

₹1081.151.84%

as on 04:01PM, 28 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Glenmark Life Sciences Performance

  • Day's Low

    Day's High

    ₹1,066
    Day's Price Range
    ₹1,139.4
  • 52 Week's Low

    52 Week's High

    ₹741.85
    52-Week Price Range
    ₹1,335.1
1 Month Return+ 19.97 %
3 Month Return+ 9.49 %
1 Year Return+ 36.7 %
Previous Close₹1,061.65
Open₹1,093.00
Volume3.86L
Upper Circuit₹1,273.95
Lower Circuit₹849.35
Market Cap₹13,009.15Cr

Glenmark Life Sciences Fundamentals

P/E Ratio

0

PEG Ratio

0

Market Cap

₹13,009.15 Cr

P/B Ratio

4.07

EPS

0

Dividend Yield

0

Sector

Pharmaceuticals

ROE

21.07

Glenmark Life Sciences Analyst Rating

based on 5 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 5 analysts offering long term price targets for Glenmark Life Sciences. An average target of ₹1296

Source: S&P Global Market Intelligence

Glenmark Life Sciences Share analysis

Glenmark Life Sciences price forecast by 5 analysts

Upside of22.07%

High

₹1360

Target

₹1296.00

Low

₹1150

Glenmark Life Sciences target price ₹1296, a slight upside of 22.07% compared to current price of ₹1081.15. According to 5 analysts rating.

Source: S&P Global Market Intelligence

Key events for Alivus Life Sciences Ltd

  • Glenmark Life Sciences Rebrands as Alivus Life Sciences - 20 Jan, 2025

    Glenmark Life Sciences has officially changed its name to Alivus Life Sciences following its acquisition by Nirma. This rebranding reflects the company's renewed vision and commitment to growth in the API and CDMO sectors, symbolizing vitality and transformation.

Insights on Alivus Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 12.98% to 13.40% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 2.82% to 3.23% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ALIVUS stock has moved up by 20.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 70.5% return, outperforming this stock by 33.8%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 20.1%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 7.85% to 6.74% in Dec 2024 quarter

Glenmark Life Sciences Financials

Value in ₹ crore
Details2021202220232024
Total Assets₹1,999.10Cr (-)₹2,472.09Cr (↑23.66%)₹2,703.98Cr (↑9.38%)₹2,854.97Cr (↑5.58%)
Total Liabilities₹1,246.35Cr (-)₹417.77Cr (↓66.48%)₹565.77Cr (↑35.43%)₹522.64Cr (↓7.62%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹195.01Cr (-)₹388.11Cr (↑99.02%)₹597.59Cr (↑53.97%)₹306.01Cr (↓48.79%)₹413.52Cr (↑35.13%)

Glenmark Life Sciences Index Inclusions

BSE Healthcare

₹41,421.50

-0.12 (-48.19%)

Nifty 500

₹21,339.55

-0.32 (-68.4%)

Nifty MidSmallcap 400

₹17,677.95

-0.2 (-36.15%)

Nifty Smallcap 250

₹15,104.05

-0.05 (-7.6%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

BSE Small-Cap

₹46,638.13

-0.35 (-165.52%)

Glenmark Life Sciences Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
75%
0.00
Foreign Institutions
6.74%
-14.14
Mutual Funds
3.23%
14.49
Retail Investors
13.4%
3.23
Others
1.63%
21.28

Glenmark Life Sciences Key Indicators

Details20202021202220232024
Return On Equity %127.8460.9129.8322.2821.07

Glenmark Life Sciences Earnings and Dividends

  • Alivus Life Sciences Ltd Earnings Results

    Alivus Life Sciences Ltd’s net profit jumped 15.32% since last year same period to ₹136.96Cr in the Q3 2024-2025. On a quarterly growth basis, Alivus Life Sciences Ltd has generated 43.68% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Alivus Life Sciences Ltd Dividends October,2023

    In the quarter ending September 2023, Alivus Life Sciences Ltd has declared dividend of ₹22.50 - translating a dividend yield of 4.02%.

    Read More about Dividends

Glenmark Life Sciences Technicals Summary

Bearish

Neutral

Bullish

Bullish

Alivus Life Sciences Ltd is currently in a Bullish trading position according to technical analysis indicators.

Glenmark Life Sciences Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹13,009.15 Cr8.37%0.51NANA
NA₹236.89 Cr278.53%0.58-₹12 Cr₹15 Cr
NA₹3,516.02 Cr68.2%0.58-₹154 Cr₹2,615 Cr
NA₹3,325.20 Cr126.56%0.70₹86 Cr₹806 Cr
NA₹41.74 Cr11.19%0.51₹1 Cr₹62 Cr

About Glenmark Life Sciences

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Life Sciences
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Alivus Life Sciences Ltd

What is Alivus Life Sciences Ltd price today?

Alivus Life Sciences Ltd share price today stands at ₹1081.15, Open: ₹1093, Previous Close: ₹1061.65, High: ₹1139.4, Low: ₹1066, 52 Week High: ₹1335.1, 52 Week Low: ₹741.85.

How to Buy Alivus Life Sciences Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Alivus Life Sciences Ltd shares

What are today's traded volumes of Alivus Life Sciences Ltd?

Today's traded volume of Alivus Life Sciences Ltd(ALIVUS) is 3.86L.

What is today's market capitalisation of Alivus Life Sciences Ltd?

Today's market capitalisation of Alivus Life Sciences Ltd(ALIVUS) is ₹13009.15Cr.

What is the 52 Week High and Low Range of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd (ALIVUS)
Price
52 Week High
₹1335.1
52 Week Low
₹741.85

How much percentage Alivus Life Sciences Ltd is down from its 52 Week High?

Alivus Life Sciences Ltd (ALIVUS) share price is ₹1081.15. It is down -19.02% from its 52 Week High price of ₹1335.1

How much percentage Alivus Life Sciences Ltd is up from its 52 Week low?

Alivus Life Sciences Ltd (ALIVUS) share price is ₹1081.15. It is up 45.74% from its 52 Week Low price of ₹741.85